Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2015; 21(22): 6924-6930
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.6924
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.6924
Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors
Rodrigo Panno Basilio-de-Oliveira, Pathology Post-Graduate Program, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil
Rodrigo Panno Basilio-de-Oliveira, Department of Pathology and Clinical Support, Federal University of Rio de Janeiro State, 22280-110 Rio de Janeiro, Brazil
Vera Lucia Nunes Pannain, Department of Pathology, Pathology Post-Graduate Program, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil
Author contributions: Basilio-de-Oliveira RP and Nunes Pannain VL contributed equally to this article; both designed the study, performed the research, analyzed the data, wrote the paper, and revised the final version to be published.
Ethics approval: The Ethics Committee of the research of the University Hospital Clementino Fraga Filho under No. 079/05.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: None of the authors of this study has received fees for serving as a speaker, a consultant and/or an advisory board member. None has received research funding from organization(s).
Data sharing: Technical appendix, statistical code, and dataset available from the corresponding author at rodrigopboliveira@gmail.com. Participant gave informed consent for data sharing.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rodrigo Panno Basilio-de-Oliveira, Associate Professor, Department of Pathology and Clinical Support, Federal University of Rio de Janeiro State, Street Alvaro Ramos 71/505, Rio de Janeiro 22280-110, Brazil. rodrigopboliveira@gmail.com
Telephone: +55-212-2041365 Fax: +55-212-5695605
Received: December 20, 2015
Peer-review started: December 21, 2015
First decision: January 22, 2015
Revised: February 23, 2015
Accepted: March 30, 2015
Article in press: March 31, 2015
Published online: June 14, 2015
Processing time: 180 Days and 8 Hours
Peer-review started: December 21, 2015
First decision: January 22, 2015
Revised: February 23, 2015
Accepted: March 30, 2015
Article in press: March 31, 2015
Published online: June 14, 2015
Processing time: 180 Days and 8 Hours
Core Tip
Core tip: Prognosis of gastrointestinal stromal tumors (GIST) is a longstanding challenge. Association of angioimmunomarkers with poor prognosis has recently been demonstrated, but few studies have evaluated the relevance of vascular endothelial growth factor (VEGF) and CD31, and none has analyzed the role of CD105 expression in prognosis. Our results suggest that angiogenic markers (intratumoral microvascular density cut-off of CD105 and CD31 besides VEGF) and Ki67 (tumor cell proliferation marker), may be prognostic factors for GIST, besides and Ki67 (tumor cell proliferation). However, further studies are necessary before considering such angiogenic molecules as possible therapeutic targets.